ArticleNature2024
Chemoproteomic discovery of a covalent allosteric inhibitor of WRN helicase.
Erratum issuedAbstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- CRISPR Screening Identifies SMARCAL1 and MRN as Modulators of WRN Dependency in MSI-H Colorectal Cancer.Cancer research · 2026Article
- Targeting WRN Helicase in Microsatellite-Instable Colorectal Cancer Induces Antitumor Immunity through Extrachromosomal Circular DNA Release.Cancer research · 2026Article
- Werner helicase inhibitor for advanced microsatellite instability solid tumors: a phase 1 trial.Nature medicine · 2026Article
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- DNA binding contributes to dominant-negative effects of a catalytically inactive RecQ4-family helicase.Nucleic acids research · 2026Article
- High-Content CRISPR Screening: Methods and Applications.MedComm · 2026Review
- Paediatric therapeutic development workshop on osteosarcoma.British journal of cancer · 2026Review
- Suppression of transcription-replication conflicts by sequence-coordinated actions of TRDMT1 and MutLα.Nature communications · 2026Article
- Microsatellite Instable Cancer Cells Acquire On-target Resistance Mutations to WRN Helicase Inhibitors.Molecular cancer therapeutics · 2026Article
- Systematic Targeting of Protein Complexes with Molecular COUPLrs.Cancer discovery · 2026Article
- Cryo-EM structures of human FANCJ reveal the mechanism of G-quadruplex unwinding and disease-associated mutations.Nature communications · 2026Article
- Scaling covalent ligand discovery through dynamic combinatorial library-versus-proteome screening.Nature communications · 2026Article
- A Global Ligandability Map of Tryptoline Butynamide Stereoprobes Identifies Covalent Inhibitors of the Actin Maturation Protease.Journal of the American Chemical Society · 2026Article
- Druggability is not static.Nature chemical biology · 2026Article
- Checkpoint inhibitors in microsatellite instability-high metastatic colorectal cancer: treatment strategies, specificities, and care management questions.ESMO gastrointestinal oncology · 2026Review
- Loss of CHTF18-RFC2/5 leads to replicative gaps and sensitivity to PARP inhibitors.NAR cancer · 2026Article
- A Covalent Allosteric Molecular Glue Suppresses NRF2-Dependent Cancer Growth.Cancer discovery · 2026Article
- Normalizing Covalent Potency for Electrophilicity with Ligand Reactivity Efficiency.Journal of medicinal chemistry · 2026Review
- dMMR killer: A conditional suicide gene that preferentially kills DNA mismatch repair-deficient cells.Molecular therapy. Nucleic acids · 2026Article
- A Global Ligandability Map of Tryptoline Butynamide Stereoprobes Identifies Covalent Inhibitors of the Actin Maturation Protease ACTMAP.bioRxiv : the preprint server for biology · 2026Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
39 authors.
Kristen A BaltgalvisVividion Therapeutics, San Diego, CA, USA.
Kelsey N LambVividion Therapeutics, San Diego, CA, USA.
Kent T SymonsVividion Therapeutics, San Diego, CA, USA.
Chu-Chiao WuVividion Therapeutics, San Diego, CA, USA.
Melissa A HoffmanVividion Therapeutics, San Diego, CA, USA.
Aaron N SneadVividion Therapeutics, San Diego, CA, USA.
Xiaodan SongVividion Therapeutics, San Diego, CA, USA.
Thomas GlazaVividion Therapeutics, San Diego, CA, USA.
Shota KikuchiVividion Therapeutics, San Diego, CA, USA.
Jason C GreenVividion Therapeutics, San Diego, CA, USA.
Donald C RognessVividion Therapeutics, San Diego, CA, USA.
Betty LamVividion Therapeutics, San Diego, CA, USA.
Maria E Rodriguez-AguirreVividion Therapeutics, San Diego, CA, USA.ORCID 0000-0002-8064-9840
David R WoodyVividion Therapeutics, San Diego, CA, USA.
Christie L EisslerVividion Therapeutics, San Diego, CA, USA.
Socorro RodilesVividion Therapeutics, San Diego, CA, USA.
Seth M NegronVividion Therapeutics, San Diego, CA, USA.
Steffen M BernardVividion Therapeutics, San Diego, CA, USA.
Eileen TranVividion Therapeutics, San Diego, CA, USA.
Jonathan PollockVividion Therapeutics, San Diego, CA, USA.
Ali TabatabaeiVividion Therapeutics, San Diego, CA, USA.
Victor ContrerasVividion Therapeutics, San Diego, CA, USA.
Heather N WilliamsVividion Therapeutics, San Diego, CA, USA.
Martha K PastuszkaVividion Therapeutics, San Diego, CA, USA.
John J SiglerVividion Therapeutics, San Diego, CA, USA.
Piergiorgio PettazzoniPharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
Markus G RudolphPharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland.ORCID 0000-0003-0447-1101
Moritz ClassenPharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
Doris BruggerPharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
Christopher ClaibornePharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
Jean-Marc PlancherPharma Research and Early Development pRED F. Hoffmann-La Roche, Ltd, Basel, Switzerland.
Isabel CuartasVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
Joan SeoaneVall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.ORCID 0000-0002-6541-5974
Laurence E BurgessVividion Therapeutics, San Diego, CA, USA.
Robert T AbrahamVividion Therapeutics, San Diego, CA, USA.
David S WeinsteinVividion Therapeutics, San Diego, CA, USA.
Gabriel M SimonVividion Therapeutics, San Diego, CA, USA.
Matthew P PatricelliVividion Therapeutics, San Diego, CA, USA. mattp@vividion.com.ORCID 0000-0002-7829-7065
Todd M KinsellaVividion Therapeutics, San Diego, CA, USA. tkinsella71c@gmail.com.ORCID 0009-0004-3156-3452
Funding
No grant is acknowledged in the PubMed record.
Abstract
WRN helicase is a promising target for treatment of cancers with microsatellite instability (MSI) due to its essential role in resolving deleterious non-canonical DNA structures that accumulate in cells with faulty mismatch repair mechanisms
Indexed as
Allosteric RegulationDrug DiscoveryEnzyme InhibitorsProteomicsWerner Syndrome HelicaseAdenosine TriphosphateAnimalsCell DeathCell Line, TumorColorectal NeoplasmsCysteineDNA Breaks, Double-StrandedFemaleHumansMaleMiceAdenosine TriphosphateCysteineEnzyme InhibitorsWerner Syndrome HelicaseWRN protein, human
Identifiers
PMID
38658751What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.